for people ages 18-65 (full criteria)
at Sacramento, California and other locations
study started
estimated completion



This study will evaluate the safety, tolerability, and efficacy of an engineered donor graft ("TregGraft"/"Orca-T", a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells) in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.

Official Title

A Multicenter Phase Ib Trial for Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With TregGraft (Orca-T), a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells


Acute Myeloid Leukemia Acute Lymphoid Leukemia Myelodysplastic Syndromes Acute Leukemia Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) hematopoietic stem cell transplantation matched related donor matched unrelated donor Leukemia Preleukemia Hematologic Neoplasms Leukemia, Lymphoid Precursor Cell Lymphoblastic Leukemia-Lymphoma TregGraft (Orca-T)


You can join if…

Open to people ages 18-65

Recipients must meet all of the following criteria:

  1. Patients must diagnosed with one of the following histopathologically confirmed diseases, for which a myeloablative hematopoietic stem cell transplant (HCT) is planned:
  2. acute myeloid, lymphoid or mixed phenotype leukemia
  3. high or very high risk myelodysplastic syndromes
  4. Myelofibrosis
  5. Blastic Plasmacytoid Dendritic Cell Neoplasm
  6. Patients with active acute leukemia (i.e. not in morphologic complete response) must have bone marrow infiltration by leukemic blasts of <= 10%,
  7. Patients must be matched to a related or unrelated donor
  8. Estimated glomerular filtration rate (eGFR) > 50 mL/minute
  9. Cardiac ejection fraction at rest ≥ 45% or shortening fraction of ≥ 27% by echocardiogram or radionuclide scan (MUGA)
  10. Diffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) ≥ 50%
  11. Total bilirubin < 2 times upper limit of normal (ULN) (patients with Gilbert's syndrome may be included where hemolysis has been excluded) and ALT/AST < 3 times ULN

You CAN'T join if...

Recipients meeting any of the following exclusion criteria will not be eligible:

  1. History of prior allogeneic HCT
  2. Currently receiving corticosteroids or other immunosuppressive therapy. Topical corticosteroids or oral systemic corticosteroid doses less than or equal to 10 mg/day are allowed.
  3. Pre-planned donor lymphocyte infusion (DLI)
  4. Planned pharmaceutical in vivo or ex vivo T cell depletion
  5. Positive for anti-donor HLA antibodies against an allele in the selected donor
  6. Karnofsky performance score < 70%
  7. Hematopoietic cell transplantation-specific Comorbidity Index (HCT-CI) > 4
  8. Uncontrolled bacterial, viral or fungal infections (currently taking antimicrobial therapy and with progression or no clinical improvement) at time of enrollment
  9. Seropositive for HIV-1 or -2 antibody, HTLV-1 or -2 antibody, Hepatitis B sAg, or Hepatitis C antibody
  10. . Any uncontrolled autoimmune disease requiring active immunosuppressive treatment
  11. . Concurrent malignancies or active disease within 1 year, except non-melanoma skin cancers that have been curatively resected
  12. . Women who are pregnant or breastfeeding


  • UC Davis accepting new patients
    Sacramento California 95817 United States
  • Stanford Health Care accepting new patients
    Stanford California 94305 United States


accepting new patients
Start Date
Completion Date
Orca Biosystems, Inc.
Sign up for this study
Phase 1 research study
Study Type
Expecting 84 study participants
Last Updated